Envestors

Type

Other

Status

Active

Location

London, United Kingdom

Total investments

20

Average round size

7M

Portfolio companies

16

Rounds per year

1.05

Lead investments

5

Follow on index

0.20

Exits

2

Stages of investment
SeedEarly Stage Venture
Areas of investment
BiotechnologyInternetSoftwareOnline PortalsHealth CareEnterprise SoftwareManufacturingMedical DeviceMedicalCloud Data Services

Summary

Envestors appeared to be the Corporate Investor, which was created in 2004. The leading representative office of defined Corporate Investor is situated in the London. The fund was located in Europe if to be more exact in United Kingdom.

The fund has no specific favorite in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Financial Exchanges, Fertility. Among the most popular portfolio startups of the fund, we may highlight Lightpoint Medical, Ebury, Cipher Surgical. For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

The important activity for fund was in 2011. This Envestors works on 21 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 1 - 5 millions dollars are the general things for fund. Considering the real fund results, this Corporate Investor is 18 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year. The increased amount of exits for fund were in 2019.

The fund was created by Nick Taylor, Oliver Woolley, Scott Haughton. The overall number of key employees were 3.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Envestors, startups are often financed by Midven, Angels 5K, Minerva Business Angel Network. The meaningful sponsors for the fund in investment in the same round are SyndicateRoom, Oxford Technology Management, Cambridge Capital Group. In the next rounds fund is usually obtained by SyndicateRoom, 83North, The FSE Group.

Show more

Investor highlights

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
20
Lead investments
5
Exits
2
Rounds per year
1.05
Follow on index
0.20
Investments by industry
  • Medical Device (4)
  • Medical (4)
  • Software (4)
  • Health Care (4)
  • Manufacturing (3)
  • Show 42 more
Investments by region
  • Canada (1)
  • United Kingdom (16)
  • South Korea (3)
Peak activity year
2011
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
12
Avg. valuation at time of investment
149M
Group Appearance index
0.50
Avg. company exit year
8
Avg. multiplicator
4.06
Strategy success index
0.10

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Lightpoint Medical 30 Dec 2014 Biotechnology, Medical Device, Medical Early Stage Venture 1M United Kingdom, England
Willog 12 Oct 2023 Logistics, Supply Chain Management, Transportation, Software, Information Technology Early Stage Venture Seoul, Seoul-t'ukpyolsi, South Korea

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.